US IPO Pipeline SEC S-1 Filings — August 26, 2026

S-1 filing signals intent to raise capital via public offering, following a $1.37/share private placement and registered direct offering that closed August 17, 2026, showing continued investor appetite

First 503B product (DARE to PLAY Sildenafil Cream) available for pre-order since December 2025, indicating early commercial traction in a high-demand segment

Consumer health product (Flora Sync LF5) launched in June 2026, diversifying revenue streams beyond prescription products

Dual-path business model (503B + consumer health) could create multiple revenue streams, reducing reliance on a single product

No material revenue expected from product sales in 2026, indicating the company is still in pre-revenue stage, which is a significant risk

Nasdaq delisting hearing held August 25, 2026, creating uncertainty about the company's listing status, which could impact investor confidence and liquidity

Negative stockholders' equity signals financial distress, potentially limiting ability to fund operations without further dilution

Need for substantial additional capital to fund operations suggests future dilution risk for existing shareholders

Smaller reporting company status may reduce regulatory burdens but also limits public float and institutional interest

The S-1 filing itself is a catalyst, as successful completion could provide a cash runway to reach key milestones

Hearing held August 25, 2026, to address non-compliance; potential delisting could severely impact stock liquidity and investor confidence

Negative stockholders' equity indicates insolvency risk, making the company highly dependent on external financing

No material revenue expected from product sales in 2026, meaning the company is pre-revenue and burning cash

Substantial additional capital required to fund operations, leading to potential dilution and/or debt burden

503B compounded products face regulatory scrutiny; any compliance issues could delay or halt product sales

Transition to dual-path model may strain resources and management focus, increasing execution risk

Consumer health market is competitive; Flora Sync LF5 may face strong competition from established brands

Proposed public offering may be priced below $1.37/share, reflecting market skepticism and potential further dilution

DARE to PLAY Sildenafil Cream is a first-in-class 503B product with pre-orders since December 2025, potentially capturing a niche market

Flora Sync LF5 launched in June 2026, entering the growing women's health probiotic market

The S-1 offering could raise significant capital to fund operations and product development, extending cash runway

Dual-path model diversifies revenue streams, reducing reliance on a single product and increasing resilience

503B pathway allows faster time-to-market compared to traditional FDA approvals, providing a competitive edge

As a smaller reporting company, Daré may be overlooked by institutional investors, creating potential for value discovery

The S-1 provides detailed information on product pipeline, allowing investors to assess future catalysts

If the offering is priced below $1.37, it may present a buying opportunity for investors who believe in the long-term potential

Daré's S-1 highlights the trend of biotech companies using public offerings to fund operations, especially those with negative equity and no revenue

The launch of DARE to PLAY Sildenafil Cream reflects the growing market for 503B compounded products, offering faster alternatives to traditional FDA-approved drugs

Flora Sync LF5 targets women's health, a sector with increasing investor attention and market demand

The Nasdaq delisting threat underscores the financial fragility of small-cap biotech companies, a common theme in the sector

Outcome of the August 25, 2026 hearing will determine listing status; monitor for any announcements

Pricing and terms of the proposed public offering; watch for SEC effectiveness and pricing date

Monitor pre-orders for DARE to PLAY Sildenafil Cream and early sales of Flora Sync LF5 for revenue traction

Next quarterly report will reveal cash position and burn rate; watch for any going concern language

Any FDA or state board actions regarding 503B products could impact operations

Watch for insider buying or selling post-offering to gauge management confidence

Any new distribution or partnership agreements for consumer health products could be a catalyst